| IPO Company Profile © ipodata.com |
| Message Board | Quote | Chart | News | SEC Filings | Peer IPO Companies |
| Orchid BioSciences, Inc. |
| 303 College Road East, Princeton, NJ 08540 * (609) 750-2200 |
| Business Description | The company is a leader in the development and commercialization of technologies, products and services designed to measure and use information related to genetic diversity. |
| Offering Information Company has | |||
| Trading As | ORCH (NASNTL) | Industry | Service (SIC 8731) |
| Type of Stock Offered | Common Shares | Filing Date | 2/18/00 |
| Domestic Shares Offered | 6,000,000 | Offer Date | 5/4/00 |
| Foreign Shares Offered | 0 | Filing Range | $8.00 - $9.00 |
| Company Shares | 6,000,000 | Offer Price | $8.00 |
| Selling Shrhldrs Shares | 0 | Gross Spread | $0.560 |
| Gross Proceeds | $48,000,000 | Selling | - - |
| Expenses | - - | Reallowance | $0.100 |
| Post-IPO Shares | 33,998,606 | Employees | - - |
| Primary Underwriting Group | ||
| Underwriter Name | Participation | Underwriter Phone |
| CS First Boston | Lead Manager | (212) 325-2000 |
| Robertson, Stephens & Company | Co-manager | (415) 989-8500 |
| Salomon Smith Barney | Co-manager | (212) 723-7300 |
| Income Statement and Cash Flow Summary | |||||||
| Prior Audited Income |
Latest Unaudited Income | ||||||
| Full Year Audited Figures | - - Months Ending | ||||||
| Figures in U.S. millions except per share data | 12/31/95 | 12/31/96 | 12/31/97 | 12/31/98 | 12/31/00 | ||
| Revenues | 2.795 | 6.230 | 3.763 | 2.781 | 1.793 | - | - |
| Income from Oper. | -0.037 | -1.215 | -9.977 | -12.345 | -22.265 | - | - |
| Net Income | -0.006 | -1.124 | -9.928 | -11.479 | -28.220 | - | - |
| E.P.S | -0.050 | -3.450 | -27.570 | -17.090 | -95.870 | - | - |
| Revenue Growth (%) | 122.90 | -39.60 | -26.10 | -35.527 | - | ||
| Net Income Growth (%) | - | - | - | - | - | ||
| Oper. Profit Margin (%) | - | - | - | - | - | - | - |
| Net Profit Margin (%) | - | - | - | - | - | - | - |
| Cash Flow - Oper. | -15.36 | - | - | ||||
| Cash Flow - Inv. | 0.02 | - | - | ||||
| Cash Flow - Fin. | 48.67 | - | - | ||||
| Balance Sheet Summary and Financial Ratios | |||||
| Balance sheet as of: 12/31/99 | Financial Ratios | ||||
| Total Assets | 94.69 | Current Assets | 37.35 | Current Ratio | 3.67 |
| Total Liab. | 103.14 | Current Liab. | 10.17 | Debt Ratio | 108.93% |
| Total Equity | -8.46 | Working Cap. | 27.17 | Debt to Equity Ratio | - |
| Cash | 33.80 | Return on Assets | - | ||
| Use Of Proceeds |
The proceeds from the proposed offering will be used for general corporate purposes including potential acquisitions and to construct or acquire a manufacturing facility. |
| Legal Counsel Registrar Auditor | |
| Issuer's Law Firm | Mintz, Levin, Cohn, Ferris, Glovsky And Popeo |
| Bank's Law Firm | Willkie Farr & Gallagher |
| Registrar/Transfer Agent | American Securities Transfer and Trust |
| Auditor | KPMG LLC |
| Send us feedback if you would like to request that we hyperlink a firm on this page | |
| Principal Shareholders | ||
| Name of Shareholder | % Owned Before | % Owned After |
| OrbiMed Advisors, LLC | 9.40 | |
| Oracle Strategic Partners, LP | 8.30 | |
| INVESCO Global Health Sciences Fund | 6.50 | |
| Sarnoff Corporation | 6.10 | |
| Smithkline Beecham plc | 5.00 | |
| Note: represents ownership of 5% or more prior to the offering. | ||